175 related articles for article (PubMed ID: 18566589)
1. Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor.
Wu J; Li W; Craddock BP; Foreman KW; Mulvihill MJ; Ji QS; Miller WT; Hubbard SR
EMBO J; 2008 Jul; 27(14):1985-94. PubMed ID: 18566589
[TBL] [Abstract][Full Text] [Related]
2. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.
Zeng X; Zhang H; Oh A; Zhang Y; Yee D
Breast Cancer Res Treat; 2012 May; 133(1):117-26. PubMed ID: 21850397
[TBL] [Abstract][Full Text] [Related]
4. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
Logan JG; Sophocleous A; Marino S; Muir M; Brunton VG; Idris AI
J Bone Miner Res; 2013 May; 28(5):1229-42. PubMed ID: 23239200
[TBL] [Abstract][Full Text] [Related]
5. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase.
Favelyukis S; Till JH; Hubbard SR; Miller WT
Nat Struct Biol; 2001 Dec; 8(12):1058-63. PubMed ID: 11694888
[TBL] [Abstract][Full Text] [Related]
6. Role of the activation loop tyrosines in regulation of the insulin-like growth factor I receptor-tyrosine kinase.
Li W; Miller WT
J Biol Chem; 2006 Aug; 281(33):23785-91. PubMed ID: 16793764
[TBL] [Abstract][Full Text] [Related]
7. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW
Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756
[TBL] [Abstract][Full Text] [Related]
8. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer.
Buck E; Gokhale PC; Koujak S; Brown E; Eyzaguirre A; Tao N; Rosenfeld-Franklin M; Lerner L; Chiu MI; Wild R; Epstein D; Pachter JA; Miglarese MR
Mol Cancer Ther; 2010 Oct; 9(10):2652-64. PubMed ID: 20924128
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of bisphosphorylated IGF-1 receptor kinase: insight into domain movements upon kinase activation.
Pautsch A; Zoephel A; Ahorn H; Spevak W; Hauptmann R; Nar H
Structure; 2001 Oct; 9(10):955-65. PubMed ID: 11591350
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine.
Khatri A; Brundage RC; Hull JM; Williams BW; Yee D; Kirstein MN
AAPS J; 2012 Mar; 14(1):1-9. PubMed ID: 22101930
[TBL] [Abstract][Full Text] [Related]
11. 1,3-Disubstituted-imidazo[1,5-a]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors.
Mulvihill MJ; Ji QS; Werner D; Beck P; Cesario C; Cooke A; Cox M; Crew A; Dong H; Feng L; Foreman KW; Mak G; Nigro A; O'Connor M; Saroglou L; Stolz KM; Sujka I; Volk B; Weng Q; Wilkes R
Bioorg Med Chem Lett; 2007 Feb; 17(4):1091-7. PubMed ID: 17127062
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
Hu YP; Patil SB; Panasiewicz M; Li W; Hauser J; Humphrey LE; Brattain MG
Cancer Res; 2008 Oct; 68(19):8004-13. PubMed ID: 18829558
[TBL] [Abstract][Full Text] [Related]
13. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS
Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of insulin-like growth factor I receptor tyrosine kinase by ethanol.
Rubin R; Harrison R; Chen XF; Corzitotto J; Hoek JB; Hallak H
Biochem Pharmacol; 2004 Nov; 68(10):2009-17. PubMed ID: 15476672
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
Lee CC; Jia Y; Li N; Sun X; Ng K; Ambing E; Gao MY; Hua S; Chen C; Kim S; Michellys PY; Lesley SA; Harris JL; Spraggon G
Biochem J; 2010 Sep; 430(3):425-37. PubMed ID: 20632993
[TBL] [Abstract][Full Text] [Related]
16. A computational strategy to understand structure-activity relationship of 1,3-disubstituted imidazole [1,5-α] pyrazine derivatives described as ATP competitive inhibitors of the IGF-1 receptor related to Ewing sarcoma.
Guaitoli V; Alvarez-Ginarte YM; Montero-Cabrera LA; Bencomo-Martínez A; Badel YP; Giorgetti A; Suku E
J Mol Model; 2020 Aug; 26(8):222. PubMed ID: 32748063
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity.
Munshi S; Kornienko M; Hall DL; Reid JC; Waxman L; Stirdivant SM; Darke PL; Kuo LC
J Biol Chem; 2002 Oct; 277(41):38797-802. PubMed ID: 12138114
[TBL] [Abstract][Full Text] [Related]
18. The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity.
Lou M; Garrett TP; McKern NM; Hoyne PA; Epa VC; Bentley JD; Lovrecz GO; Cosgrove LJ; Frenkel MJ; Ward CW
Proc Natl Acad Sci U S A; 2006 Aug; 103(33):12429-34. PubMed ID: 16894147
[TBL] [Abstract][Full Text] [Related]
19. Extracellular vimentin interacts with insulin-like growth factor 1 receptor to promote axonal growth.
Shigyo M; Kuboyama T; Sawai Y; Tada-Umezaki M; Tohda C
Sci Rep; 2015 Jul; 5():12055. PubMed ID: 26170015
[TBL] [Abstract][Full Text] [Related]
20. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
